Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...